pharmaphorum February 19, 2024
AstraZeneca’s Tagrisso can be used alongside chemotherapy as a frontline therapy for EGFR-positive non-small cell lung cancer (NSCLC), according to the FDA, consolidating its position as the standard of care in newly diagnosed patients.
The US regulator has approved the drug after a priority review on the strength of data from the FLAURA 2 study showing that the combination of EGFR inhibitor Tagrisso (osimertinib) and chemo cut the risk of disease progression or death by 38% compared to Tagrisso alone in treatment-naïve EGFR-positive NSCLC patients.
The study, which was published in the New England Journal of Medicine last November, revealed that progression-free survival was extended by around nine months with the combination versus Tagrisso alone.
The jury is out on...
Today's Sponsors
Today's Sponsor